

FROM THE INVESTIGATORS

Non-Hodgkin lymphomas (NHLs) are a group of cancers of the blood that develop from white blood cells called lymphocytes. Lymphocytes are part of the immune system and help defend the body against infections.

There are many subtypes of NHL, and each subtype may have different causes and need different treatments. As a result, patients with NHL need different types of care.

The Lymphoma Epidemiology of Outcomes (LEO) Study is collecting data and samples that will help us understand the causes for different types of NHL, the best treatments, and the best ways to help survivors. Your participation in this study is key to our success.



Lymphoma Epidemiology of Outcomes

HOW CAN YOU IMPACT
LYMPHOMA RESEARCH?

JOIN THE
LEO
COHORT STUDY

PARTICIPATE IN LEO

Am I Eligible to Participate?

- ✓ Must be age 18 years and older
- ✓ Must join within 6 months of diagnosis date

What Does Participation Mean?

- ◇ Provide written consent
- ◇ Provide a blood sample at enrollment
- ◇ Complete questionnaires at enrollment and during follow-up
- ◇ Grant access to your medical records and pathology samples
- ◇ Additional blood samples may also be collected during routine blood

GOALS

- Support research that finds new and better ways to improve the length and quality of life of people living with non-Hodgkin lymphoma
- Create a long-term cohort registry of over 12,000 newly diagnosed non-Hodgkin lymphoma patients
- Create a bank of blood and tissue specimens
- Collect clinical and risk factor data from participants at enrollment and over time.
- Follow patients over time to determine possible causes, optimal treatment, and survivorship of NHL.

LEO OVERVIEW

The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study is a collaboration between 8 prominent medical centers and universities around the United States. The goal of LEO is to build a large and diverse observational cohort study to support a broad research agenda aimed at identifying new clinical, epidemiologic, genetic, tumor, and treatment factors that significantly influence non-Hodgkin lymphoma (NHL) survivorship.

To accomplish this, we plan to enroll over 12,000 participants who have been recently diagnosed with NHL. We are following them over time to understand what predicts better lymphoma outcomes and survivorship.

Your participation in LEO will greatly help us to understand these factors and use this knowledge to help improve someone's chance of surviving lymphoma and to improve his or her quality of life following treatment for lymphoma.

LEO COHORT LOCATIONS

